Reports not available.

Anovolutory infertility . Hypogonadotrophic hypogonadism in males and females Follicle stimulation in IVF

Sensitivity reactions Ovarian enlargement or cysts or rupture Hyperstimulation presenting as renal failure, hypovalaemic shock, arterial thromboem- Multiple pregnancies. Abdominal pain GI upset Hemopritoneum

Pregnancy, Primary ovarian failure Uncontrolled abnormal vaginal bleeding Ovarian cysts or enlargement Special precautions: Patients with endocrine disorders or intracranial lesions, must be treated before therapy Perform skin tests before treatment in susceptible patients Do not complete gynacological and endocrinological exam. first Monitor appropiate lab values Discontinue if estrogen values or other evidence of ovarian hyperstimulation syndrome OHSS occur If ovaries are enlarged on last day of theapy do not administer hCG, this decreases the risk of OHSS Thromboembolic disorders Lactation

Anovolutory infertility . Hypogonadotrophic hypogonadism in males and females Follicle stimulation in IVF

Dosage-

Initial dosage- Initial IM dose is 75IU FSH /75 IU LH ( 1 amp /day for 7 to 12 days , follow by 10,000 IU HCG 1 day after the last dose of menotropins Do not exceed 12 days of menotropins admin.

Test the patient until indices of oestrogenic activity are equal to are greater than those of normal individual Repeat dosage- If there is evidence of ovulation, but no pregnancy, repeat the regimen for at least 2 more courses before increasing the dose to 150IU FSH/150 IU LH ( 2 amp ) per day for 7 to 12 days

Pharmacology:

Produces ovarian follicular growth in women who do not have primary ovarian failure. In men, menotropin administered concomittantly with HCG for atleast 3 months induces spermatogenesis with primary or secondary pituitary hypofunction who have acheived adequate masculinasation with prior HCG therapy.

Contraindicated for use during pregnancy and lactation Observe caution